OCT 29, 2014 6:00 AM PDT

Nanotechnologies for Precision Medicine

Speaker
  • Director, NSF IGERT Nanomedicine Science and Technology Program, Director, Electronic Materials Research Institute, Arts and Sciences Distinguished Professor of Physics, Lecturer on Radiation
    Biography
      Srinivas Sridhar is Arts and Sciences Distinguished Professor of Physics at Northeastern University, and Visiting Professor of Radiation Oncology, Harvard Medical School. He is the Director and Principal Investigator of Nanomedicine Science and Technology, an IGERT (Integrative Graduate Education and Research Training) program funded by the National Cancer Institute and the National Science Foundation. He is the founding director of the Electronic Materials Research Institute, an interdisciplinary center with research and education thrusts in nanophotonics and nanomedicine. From 2004 to 2008 he served as Vice Provost for Research at Northeastern University, overseeing the Universitys research portfolio. An elected Fellow of the American Physical Society, Sridhars current areas of research are nanomedicine and nanophotonics. He has published more than 160 articles on his work in nanomedicine, nanophotonics, metamaterials, quantum chaos, superconductivity and collective excitations in materials.

    Abstract

    The modern era of Precision Medicine requires targeted delivery of molecular inhibitors that control key processes in disease pathways. PARP (Poly ADP Ribose Polymerase) plays a crucial role in the DNA repair pathways in a cell, rendering it the Achilles Heel specifically in cancer cells. We have developed novel injectable nanoformulations of PARP inhibitors that have superior bioavailability and tumor accumulation compared with available oral formulations. Extensive in vitro and in vivo studies have been carried out in ovarian, breast and prostate cancer models. These results imply an important role for the PARPi nanoformulations as chemo and radio-sensitizers enabling mono- and combination nanotherapeutic approaches for several cancers.

    Theranostic nanoplatforms combine multiple functionalities including multi-modal imaging, targeting to the disease site, and delivery of the drug payload through sustained as well as triggered drug release. We discuss the applications of these nanoplatforms in local chemotherapy with INCERT implants, and MR/SPECT/optical multi-modal imaging using iron oxide nanoparticles.

    Supported by the National Science Foundation, National Cancer Institute, DoD CDMRP, Mazzone Foundation and CIMIT.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    Loading Comments...
    Show Resources
    Attendees
    • See more